Improving CLL Point-of-Care Decisions Utilizing BTK Inhibitors: Aligning Patient and Provider Goals

Access Activity

Overview / Abstract:

Target Audience

The intended audience for this activity are hematologic oncologists, hematologists, oncology advanced practice providers (NPs and PAs), oncology nurses, and other clinicians involved in the management of patients with CLL.

Learning Objectives

Upon completion of this activity, participants should be better able to:

Review patient-specific criteria that determine eligibility for first-line and subsequent CLL therapies
List the emerging combination regimens, including BTK inhibitors
Discuss recent and new data supporting the role of BTK inhibitors in r/r CLL
Integrate patient perspectives and priorities into comprehensive care-team management of CLL


Oct 22, 2022


Nursing CNE, Physician CME



Credits / Hours

1.50 AMA PRA Category 1 Credit(s)™



Presenters / Authors / Faculty


Matthew S. Davids, MD, MMSc

Associate Professor of Medicine
Director of Clinical Research, Division of Lymphoma
Harvard Medical School
Dana-Farber Cancer Institute

Susan M. O’Brien, MD

Associate Director for Clinical Sciences
Chao Family Comprehensive Cancer Center
Medical Director, Sue & Ralph Stern Center for
Clinical Trials and Research Chao Family Endowed Chair for Cancer Clinical Science
Division of Hematology/Oncology, School of Medicine
University of California Irvine

Sponsors / Supporters / Grant Providers

AstraZeneca; Pharmacyclics LLC, an AbbVie Company; and Janssen Biotech, Inc.

Keywords / Search Terms

Relias LLC Relias LLC., FreeCME., BTK Inhibitors Free CE CME

Access Activity

CORE Higher Education Group,, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the website or within our mobile apps.CORE Higher Education Group,, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or within our mobile apps. For complete details, please read the Terms of Service. Site Map